Back to Search Start Over

Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants

Authors :
Murali, K
Dwarte, TM
Nikfarjam, M
Tucker, KM
Vaughan, RB
Efthymiou, M
Collins, A
Spigelman, AD
Salmon, L
Johns, AL
Williams, DB
Delatycki, MB
John, T
Stoita, A
Murali, K
Dwarte, TM
Nikfarjam, M
Tucker, KM
Vaughan, RB
Efthymiou, M
Collins, A
Spigelman, AD
Salmon, L
Johns, AL
Williams, DB
Delatycki, MB
John, T
Stoita, A
Publication Year :
2021

Abstract

BACKGROUND: The Australian Pancreatic Cancer Screening Program (APCSP) offers endoscopic ultrasound surveillance for individuals at increased risk of pancreatic ductal adenocarcinoma (PDAC) with all participants requiring assessment by a Familial Cancer Service before or after study enrolment. METHODS: Individuals aged 40-80 years (or 10 years younger than the earliest PDAC diagnosis) were eligible for APCSP study entry if they had 1) ≥ two blood relatives with PDAC (at least one of first-degree association); 2) a clinical or genetic diagnosis of Hereditary Pancreatitis or Peutz-Jeghers syndrome irrespective of PDAC family history; or 3) a known PDAC predisposition germline pathogenic variant (BRCA2, PALB2, CDKN2A, or Lynch syndrome) with ≥one PDAC-affected first- or second-degree relative. Retrospective medical record review was conducted for APCSP participants enrolled at the participating Australian hospitals from January 2011 to December 2019. We audited the genetic investigations offered by multiple Familial Cancer Services who assessed APCSP participants according to national guidelines, local clinical protocol and/or the availability of external research-funded testing, and the subsequent findings. Descriptive statistical analysis was performed using Microsoft Excel. RESULTS: Of 189 kindreds (285 participants), 50 kindreds (71 participants) had a known germline pathogenic variant at enrolment (BRCA2 n = 35, PALB2 n = 6, CDKN2A n = 3, STK11 n = 3, PRSS1 n = 2, MLH1 n = 1). Forty-eight of 136 (35%) kindreds with no known germline pathogenic variant were offered mutation analysis; 89% was clinic-funded, with increasing self-funded testing since 2016. The relatively low rates of genetic testing performed reflects initial strict criteria for clinic-funded genetic testing. New germline pathogenic variants were detected in five kindreds (10.4%) after study enrolment (BRCA2 n = 3 kindreds, PALB2 n = 1, CDKN2A n = 1). Of note, only eight kindreds were reassessed by a

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315678347
Document Type :
Electronic Resource